# TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC

> **NCT06914297** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 10 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** TQB2450 injection + oral progestin

## Key facts

- **NCT ID:** NCT06914297
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-21
- **Primary completion:** 2027-10-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06914297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06914297, "TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06914297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*